more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$72.33 USD

+1.96 (2.79%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $72.35 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Zacks News

Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research Published on February 28,2022

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research Published on February 28,2022

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) fourth-quarter results benefit from Technologies & Equipment business.

Inari Medical (NARI) Gains 12.5% Despite In-Line Q4 Earnings

by Zacks Equity Research Published on February 28,2022

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research Published on February 28,2022

Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.

Thermo Fisher (TMO) Extends Collaboration With Moderna

by Zacks Equity Research Published on February 28,2022

Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.

Here's Why Henry Schein (HSIC) is a Great Momentum Stock to Buy

by Zacks Equity Research Published on February 25,2022

Does Henry Schein (HSIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

HSICPositive Net Change

Thermo Fisher (TMO) COVID Test Sales Grow, FX Woes Persist

by Zacks Equity Research Published on February 25,2022

Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

by Debanjana Dey Published on February 25,2022

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Are These Medical Stocks a Great Value Stocks Right Now?

by Zacks Equity Research Published on February 25,2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on February 25,2022

Here is how Henry Schein (HSIC) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research Published on February 25,2022

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

by Zacks Equity Research Published on February 25,2022

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research Published on February 25,2022

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.